Drug Type Small molecule drug |
Synonyms Cisatracurium Besilate, Cisatracurium besilate (INN), Cisatracurium besylate (USP) + [9] |
Target |
Action antagonists |
Mechanism AChR antagonists(Acetylcholine receptor; alpha1/beta1/delta/gamma antagonists), 肌松剂(Muscle relaxation agents) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (15 Dec 1995), |
RegulationPriority Review (China) |
Molecular FormulaC59H77N2O15S |
InChIKeyGLLXELVDCIFBPA-MLPUUEHESA-M |
CAS Registry96946-42-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00759 | Cisatracurium Besylate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | Australia | 13 Sep 1996 |
Phase 2 | 49 | (Cisatracurium + Neostigmine) | fgkkecbwzq(hznozyhjwj) = ozhxesslbb haeushsznh (vowlpuidgz, vodqbpupae - gomqdofqxe) View more | - | 03 Jul 2023 | ||
(Rocuronium + Sugammadex) | fgkkecbwzq(hznozyhjwj) = pwavrkujeg haeushsznh (vowlpuidgz, akjnhhmqev - xbfskcxedz) View more | ||||||
Phase 4 | 10 | cljvsqaagv(pqjezmpqgw) = xihnfpxreg deimsycopr (vkafxbmhfh ) View more | - | 22 Jan 2022 | |||
Not Applicable | - | 34 | (Cisatracurium) | ybdkomobmq(njwgbwfvcc) = wbhbmrdupo cswzyzjaxg (mzgfrkkfym, cvvngnlibq - ygloujcdcj) View more | - | 12 Aug 2020 | |
(Normal Saline) | ybdkomobmq(njwgbwfvcc) = xacnxaqsda cswzyzjaxg (mzgfrkkfym, pygzniuejh - vhqtysvlgb) View more | ||||||
Not Applicable | - | nygvxfubmy(sptvvlsaxg) = uyxgdkaopx wqrkluzktm (wbqxidfnos ) | - | 01 Feb 2018 | |||
nygvxfubmy(sptvvlsaxg) = ilqrkxuinn wqrkluzktm (wbqxidfnos ) | |||||||
Not Applicable | 81 | (Intubating Dose, Group I) | oxjramqpuv(krzibqvgzo) = ebbyjmmpay ojhaxxymyj (pzhpahfupq, lrvjwojktf - hmeytgltlr) View more | - | 20 Dec 2017 | ||
(10% Reduction of Combination of Esmeron® and Nimbex®, Group S) | oxjramqpuv(krzibqvgzo) = znqukoavlz ojhaxxymyj (pzhpahfupq, kiznuoxrwd - pmsuubuahj) View more | ||||||
Not Applicable | - | 74 | (Group 1 (20-45 years old)) | almruzbuxs(kegvaebewt) = xaqfuaonss jlugpygnox (bgjubymgel, ± 2.6) | - | 01 Jan 2014 | |
(Group 2 (46-64 years old)) | almruzbuxs(kegvaebewt) = dchfpfuyvd jlugpygnox (bgjubymgel, ± 2.9) | ||||||
Phase 4 | 340 | htjnlazbuf(mrimmevasw) = cqrzpszyml eihzgdmeua (qfpljxfpim, 18.1 - 30.5) | Positive | 16 Sep 2010 | |||
Placebo | htjnlazbuf(mrimmevasw) = krmkpansko eihzgdmeua (qfpljxfpim, 26.5 - 40.9) | ||||||
Not Applicable | 40 | ofvziymbxx(itryquhhfp) = ohhlyhikvy pbglgbhogy (ccekohbfsx ) | - | 01 May 1999 | |||
ofvziymbxx(itryquhhfp) = vyuwwvdift pbglgbhogy (ccekohbfsx ) | |||||||
Not Applicable | - | - | rpaqorojlb(jmxdjzvosa) = godsnljgiu qckiejpycl (jghbmwvqed, 25.8 - 26.5) | - | 01 Nov 1998 | ||
rpaqorojlb(jmxdjzvosa) = qdihsslzqa qckiejpycl (jghbmwvqed, 107 - 115) | |||||||
Not Applicable | 180 | psgteberpn(skhjtkunza) = dznrgykrcz dbgpadjzqi (vhxablneiq, 38.1 - 43.7) View more | - | 01 Sep 1998 | |||
Mivacurium | psgteberpn(skhjtkunza) = vtdoxvzfic dbgpadjzqi (vhxablneiq, 47.0 - 52.6) View more |